How have ZLDAF shares performed in 2024?

Zelira Therapeutics' stock was trading at $0.5896 on January 1st, 2024. Since then, ZLDAF stock has decreased by 60.5% and is now trading at $0.2328. View the best growth stocks for 2024 here .

Are investors shorting Zelira Therapeutics?

Zelira Therapeutics saw a decrease in short interest in the month of June. As of June 15th, there was short interest totaling 500 shares, a decrease of 16.7% from the May 31st total of 600 shares. Based on an average trading volume of 100 shares, the days-to-cover ratio is presently 5.0 days. View Zelira Therapeutics' Short Interest .

When did Zelira Therapeutics' stock split?

Zelira Therapeutics's stock reverse split before market open on Monday, April 18th 2022. The 1-175 reverse split was announced on Monday, April 18th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How do I buy shares of Zelira Therapeutics?

Shares of ZLDAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:ZLDAF

Zelira Therapeutics (ZLDAF) Stock Price, News & Analysis

$0.23

+0.04 (+21.76%)

(As of 07/3/2024 02:37 PM ET)

Compare

Today's Range: $0.23
▼
$0.23
50-Day Range: $0.19
▼
$0.50
52-Week Range: $0.19
▼
$1.29

Volume: 1,000 shs
Average Volume: 1,073 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Short Interest

Get Zelira Therapeutics alerts:

Ad Behind the Markets

Major Pharma Deals Propel This Undervalued AI Stock

You need to check out this game-changing biotech stock. Their physics-based software can model how molecules behave and identify ideal drug candidates in record time. Big Pharma is taking notice.

Reveal the AI Company Disrupting Drug Discovery Here >>>

About Zelira Therapeutics Stock (OTCMKTS:ZLDAF)

Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. The company offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. It also provides over the counter products, including SprinJene, an oral care product; and RAF FIVE, a dermatology product, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia.

ZLDAF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ZLDAF Stock News Headlines

July 1 at 1:40 AM | americanbankingnews.com

Short Interest in Zelira Therapeutics Limited (OTCMKTS:ZLDAF) Declines By 16.7%

See More Headlines

Receive ZLDAF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zelira Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: OTCMKTS:ZLDAF
CUSIP: N/A
CIK: N/A
Web: www.zeldatherapeutics.com
Phone: (186) 558-0886
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Mr. Osagie O. Imasogie Esq. (Age 62)
Founder & Chairman
Comp: $96.48k
Dr. Oludare Odumosu
MD, Global CEO & Director
Mr. Greg Blake
Executive Director
Mr. Timothy Ryan Slate
Company Secretary & Non-Executive Director
Mr. Rahul Ganesan
Vice President of Finance & Accounting
Dr. Patty Washer
Clinical Trial Consultant

Key Competitors

View All Competitors

ZLDAF Stock Analysis - Frequently Asked Questions

How have ZLDAF shares performed in 2024?: Zelira Therapeutics' stock was trading at $0.5896 on January 1st, 2024. Since then, ZLDAF stock has decreased by 60.5% and is now trading at $0.2328.
View the best growth stocks for 2024 here.
Are investors shorting Zelira Therapeutics?: Zelira Therapeutics saw a decrease in short interest in the month of June. As of June 15th, there was short interest totaling 500 shares, a decrease of 16.7% from the May 31st total of 600 shares. Based on an average trading volume of 100 shares, the days-to-cover ratio is presently 5.0 days.
View Zelira Therapeutics' Short Interest.
When did Zelira Therapeutics' stock split?: Zelira Therapeutics's stock reverse split before market open on Monday, April 18th 2022. The 1-175 reverse split was announced on Monday, April 18th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.
How do I buy shares of Zelira Therapeutics?: Shares of ZLDAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.